TY - JOUR
T1 - Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma
T2 - A single institution experience
AU - Chen, Weina
AU - Karandikar, Nitin J.
AU - McKenna, Robert W.
AU - Kroft, Steven H.
PY - 2007/1
Y1 - 2007/1
N2 - Essentially all cases of precursor B-lymphoblastic leukemiaAymphoma (B-ALL) demonstrate multiple immunophenotypic aberrancies relative to normal maturing B-cell precursors (hematogones). The stability of these aberrancies has relevance to follow-up minimal residual disease analysis. We compared the immunophenotypes at diagnosis and relapse in 51 childhood and adult B-ALLs with flow cytometry (FC) using broad antibody panels. A total of 446 aberrancies were present at diagnosis (median, 9 per case; range, 2-14). All cases retained multiple aberrancies at relapse (median, 8 per case; range, 2-14). Antibody panels at relapse allowed assessment of 383 (85.9%) of the initial 446 aberrancies. Of these, 299 (78.1%) were persistent and 84 (21.9%) were lost at relapse. Overall, 73% of cases showed a loss of at least 1 aberrancy at relapse. However, new aberrancies were detected in 60% of cases. These findings suggest that FC is suitable for the detection of residual B-ALL, provided that follow-up studies are not too narrowly targeted.
AB - Essentially all cases of precursor B-lymphoblastic leukemiaAymphoma (B-ALL) demonstrate multiple immunophenotypic aberrancies relative to normal maturing B-cell precursors (hematogones). The stability of these aberrancies has relevance to follow-up minimal residual disease analysis. We compared the immunophenotypes at diagnosis and relapse in 51 childhood and adult B-ALLs with flow cytometry (FC) using broad antibody panels. A total of 446 aberrancies were present at diagnosis (median, 9 per case; range, 2-14). All cases retained multiple aberrancies at relapse (median, 8 per case; range, 2-14). Antibody panels at relapse allowed assessment of 383 (85.9%) of the initial 446 aberrancies. Of these, 299 (78.1%) were persistent and 84 (21.9%) were lost at relapse. Overall, 73% of cases showed a loss of at least 1 aberrancy at relapse. However, new aberrancies were detected in 60% of cases. These findings suggest that FC is suitable for the detection of residual B-ALL, provided that follow-up studies are not too narrowly targeted.
KW - Flow cytometry
KW - Immunophenotypic stability
KW - Minimal residual disease
KW - Precursor B-All
KW - Precursor B-lymphoblastic leukemia/lymphoma
UR - http://www.scopus.com/inward/record.url?scp=34249077296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249077296&partnerID=8YFLogxK
U2 - 10.1309/7R6MU7R9YWJBY5V4
DO - 10.1309/7R6MU7R9YWJBY5V4
M3 - Article
C2 - 17145625
AN - SCOPUS:34249077296
SN - 0002-9173
VL - 127
SP - 39
EP - 46
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 1
ER -